RNU6-1238P

Across TCGA pan-cancer cohorts, RNU6-1238P RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of RNU6-1238P’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where RNU6-1238P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types RNU6-1238P is over-expressed in tumor.

STAD, LUAD, and KIRC are the cancer types where RNU6-1238P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RNU6-1238P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Female	III,IV	+0.700	<.001	7	view →
LUAD	Male	II,III,IV	+0.786	.007	5	view →
KIRC	All	IV	+0.180	.009	5	view →
COAD	All	All	+0.257	.013	4	view →
LUSC	All	All	+0.253	.016	2	view →
LIHC	All	All	+0.142	.021	2	view →
CHOL	All	All	+0.681	.032	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

RNU6-1238P–STAD

Open the STAD breakdown →